retatrutide eli lilly phase 2 results Lilly's triple agonist delivers up to 71.2 lbs of weight loss Retatrutide, Eli Lilly's next generation

Improving Aesthetic Results for GLP-1 Patients with Sofwave and Pure Impact Date Written by James Bartholomeusz Revised by Jessica Weiser, MD GLP-1 therapies are driving unprecedented weight loss in patients, but they frequently result in a variety of issues ranging from muscle atrophy to skin laxity

Self-pay vial programs like Lilly Direct (currently selling Zepbound vials at to per month depending on dose) may eventually expand to retatrutide

July 11, 2025

Fully online consultations Licensed provider network Pharmacy fulfillment through regulated partners Fast, discreet delivery All medical decisions are made independently by licensed providers, and prescriptions are only issued when appropriate

That enables traceability should adverse events occur

It invented a new GLP-1 mimic, semaglutide, that could be injected once a week